Claims for Patent: 11,091,759

Summary for Patent: 11,091,759

Title:	Methods and compositions for treating a Serpinc1-associated disorder
Abstract:	The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
Inventor(s):	Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
Assignee:	Genzyme Corp
Application Number:	US15/371,300
Patent Claims:	1. A method of preventing at least one hemophilia symptom in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50-90 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule comprises a sense strand and an antisense strand; wherein the sense strand comprises the sequence 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the antisense strand comprises the sequence 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein a ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 2. A method of treating a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50-90 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule comprises a sense strand and an antisense strand; wherein the sense strand comprises the sequence 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the antisense strand comprises the sequence 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein a ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 3. A method of preventing or reducing the frequency of bleeding episodes in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50-90 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule comprises a sense strand and an antisense strand; wherein the sense strand comprises the sequence 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the antisense strand comprises the sequence 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein a ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 4. A method of reducing the annual bleeding rate (ABR) in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50-90 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule comprises a sense strand and an antisense strand; wherein the sense strand comprises the sequence 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the antisense strand comprises the sequence 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein a ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 5. A method of reducing the annual spontaneous bleeding rate (AsBR) in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50-90 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule comprises a sense strand and an antisense strand; wherein the sense strand comprises the sequence 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the antisense strand comprises the sequence 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein a ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 6. The method of claim 1, 2, 3, 4, or 5, wherein the dose of the dsRNA molecule is administered to the subject once a month. 7. The method of claim 1, 2, 3, 4, or 5, wherein the dsRNA molecule is administered to the subject at a dose of 80 mg. 8. The method of claim 1, 2, 3, 4, or 5, wherein the subject is a hemophilia A patient with inhibitors or a hemophilia B patient with inhibitors. 9. The method of claim 1, 2, 3, 4, or 5, wherein the subject is a hemophilia A patient without inhibitors or a hemophilia B patient without inhibitors. 10. The method of claim 1, 2, 3, 4, or 5, wherein administration of the dsRNA molecule to the subject lowers Serpincl activity in the subject by about 70% to about 95%. 11. The method of claim 1, 2, 3, 4, or 5, wherein administration of the dsRNA molecule to the subject increases peak thrombin levels in the subject to within the range of peak thrombin levels in a subject that does not have hemophilia A or hemophilia B. 12. The method of claim 1 or 2, wherein administration of the dsRNA molecule to the subject is sufficient to achieve peak thrombin generation levels in the subject to about the same level achieved by administration to the subject of Factor VIII. 13. The method of claim 1 or 2, wherein administration of the dsRNA molecule to the subject is sufficient to achieve peak thrombin generation levels of greater than about 40% in the subject. 14. The method of claim 1 or 2, wherein administration of the dsRNA molecule to the subject decreases the annual bleeding rate (ABR) of the subject by about 80 to about 95% as compared to the median historical on-demand ABR of subjects having the hemophilia and not administered the dsRNA molecule. 15. The method of claim 1 or 2, wherein the dsRNA molecule is administered to the subject in a buffered solution. 16. The method of claim 15, wherein the buffered solution is phosphate buffered saline. 17. The method of claim 1, 2, 3, 4, or 5, wherein the human subject is between about 19 and 61 years of age. 18. A method of preventing at least one hemophilia symptom in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 80 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 19. A method of treating a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 80 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G,and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 20. A method of preventing or reducing the frequency of bleeding episodes in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 80 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 21. A method of reducing the annual bleeding rate (ABR) in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 80 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 22. A method of reducing the annual spontaneous bleeding rate (AsBR) in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 80 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′-GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 23. The method of claim 18, 19, 20, 21, or 22, wherein the dsRNA molecule is administered to the subject once a month. 24. The method of claim 23, wherein the subject is a hemophilia A patient with inhibitors or a hemophilia B patient with inhibitors. 25. The method of claim 23, wherein the subject is a hemophilia A patient without inhibitors or a hemophilia B patient without inhibitors. 26. The method of claim 4 or 21, wherein the administration reduces ABR of the subject to one or less. 27. The method of claim 5 or 22, wherein the administration reduces AsBR of the subject to zero. 28. The method of claim 1, 2, 3, 4, or 5, wherein the dsRNA molecule is administered to the subject at a dose of 50 mg. 29. A method of preventing at least one hemophilia symptom in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′- GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 30. A method of treating a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′- GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 31. A method of preventing or reducing the frequency of bleeding episodes in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′- GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 32. A method of reducing the annual bleeding rate (ABR) in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′- GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 33. A method of reducing the annual spontaneous bleeding rate (AsBR) in a human subject having hemophilia A or hemophilia B, comprising subcutaneously administering to the human subject in need thereof a dose of 50 mg of a double stranded ribonucleic acid (dsRNA) molecule about once a month, wherein the dsRNA molecule has a sense strand, an antisense strand, and a ligand; wherein the sequence of the sense strand consists of 5′- GfsgsUfuAfaCfaCfCfAfuUfuAfcUfuCfaAf-3′ (SEQ ID NO:13) and the sequence of the antisense strand consists of 5′-usUfsgAfaGfuAfaAfuggUfgUfuAfaCfcsasg-3′ (SEQ ID NO:14), wherein a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, C, G, and U, respectively; and s is a phosphorothioate linkage; and wherein the ligand is conjugated to the 3′ end of the sense strand as shown in the following schematic: wherein X is O. 34. The method of claim 29, 30, 31, 32, or 33, wherein the dsRNA molecule is administered to the subject once a month. 35. The method of claim 34, wherein the subject is a hemophilia A patient with inhibitors or a hemophilia B patient with inhibitors. 36. The method of claim 34, wherein the subject is a hemophilia A patient without inhibitors or a hemophilia B patient without inhibitors. 37. The method of claim 32, wherein the administration reduces ABR of the subject to one or less. 38. The method of claim 33, wherein the administration reduces AsBR of the subject to zero.